Search results
Search results from www.aesgp.eu
| Ingredient | ATC Level 1 | ATC Level 2 | Year Of Switch | Country | Status | Additional Information |
|---|---|---|---|---|---|---|
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | — | Argentina | Rx | Not registered or not marketed. |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | 2004 | Australia | OTC | Effective 1 May 2004, S4 (prescription) to S3 (pharmacist only) switch for products containing max 120mg of orlistat per dosage unit. All other preparations remain S4. Effective 1 October 2007, Schedule H (S3 substances that may be advertised to the public) entry deleted, meaning consumer advertising no longer allowed. |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | — | Austria | OTC | Orlistat 60mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 12 January 2009. The switch was also implemented in Croatia, Norway and Switzerland. |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | 2009 | Belgium | OTC | Orlistat 60mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 12 January 2009. The switch was also implemented in Croatia, Norway and Switzerland. |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | 2009 | Bulgaria | OTC | Orlistat 60mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 12 January 2009. The switch was also implemented in Croatia, Norway and Switzerland. |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | — | Canada | Rx | — |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | — | Chile | Rx | — |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | 2005 | China | OTC | 60mg & 120mg capsules and 120mg tablets. |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | — | Colombia | Rx | — |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | 2010 | Croatia | OTC | Orlistat 60 mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 12 January 2009. The switch was also implemented in Croatia, Norway and Switzerland. |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | 2009 | Czech Republic | OTC | Orlistat 60 mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 12 January 2009. The switch was also implemented in Croatia, Norway and Switzerland. |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | 2009 | Denmark | OTC | Orlistat 60 mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 12 January 2009. The switch was also implemented in Croatia, Norway and Switzerland. |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | 2009 | Estonia | OTC | Orlistat 60 mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 12 January 2009. The switch was also implemented in Croatia, Norway and Switzerland. |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | 2009 | Finland | OTC | Orlistat 60 mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 12 January 2009. The switch was also implemented in Croatia, Norway and Switzerland. |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | 2009 | France | OTC | Orlistat 60 mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 12 January 2009. The switch was also implemented in Croatia, Norway and Switzerland. |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | 2009 | Germany | OTC | Orlistat 60 mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 12 January 2009. The switch was also implemented in Croatia, Norway and Switzerland. |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | 2009 | Greece | OTC | Orlistat 60 mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 12 January 2009. The switch was also implemented in Croatia, Norway and Switzerland. |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | 2009 | Hungary | OTC | Orlistat 60 mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 12 January 2009. The switch was also implemented in Croatia, Norway and Switzerland. 210mg tablets have Rx status. |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | 2009 | Ireland | OTC | Orlistat 60 mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 12 January 2009. The switch was also implemented in Croatia, Norway and Switzerland. Supply through pharmacies only. |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | 2009 | Italy | OTC | Orlistat 60 mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 12 January 2009. The switch was also implemented in Croatia, Norway and Switzerland. Orlistat 60mg has SOP (non-advertisable) status in Italy. |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | — | Japan | N.R. | — |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | 2009 | Lithuania | OTC | Orlistat 60 mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 12 January 2009. The switch was also implemented in Croatia, Norway and Switzerland. |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | — | Mexico | OTC | Indicated in the treatment of over-weight and obesity in adults over 18 years of age. Available as 60mg capsules, maximum daily dose 180mg, maximum pack size 90 capsules, maximum duration of treatment 1 year. Pharmacy supply only. |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | 2005 | New Zealand | OTC | Pharmacist only. Consumer advertising permitted. |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | 2009 | Norway | OTC | Orlistat 60 mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 12 January 2009. The switch was also implemented in Croatia, Norway and Switzerland. |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | 2005 | Philippines | OTC | — |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | 2009 | Poland | OTC | Orlistat 60 mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 12 January 2009. The switch was also implemented in Croatia, Norway and Switzerland. |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | 2009 | Portugal | OTC | Orlistat 60 mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 12 January 2009. The switch was also implemented in Croatia, Norway and Switzerland. Available in 27mg and 60mg tablets. |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | — | Romania | Rx | ~Capsules ~blisters and glass vials containing 21, 42 and 84 capsules./20 mg administered with water, immediately before, during or at most one hour after each main meal/Doses of orlistat greater than 120 mg three times a day do not have demonstrated additional benefit. |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | 2011 | Russia | OTC | 60mg capsules for weight loss in adults over 18 years of age. Maximum pack size, maximum dose and maximum daily dose: 180mg. No product currently marketed. |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | 2005 | Singapore | OTC | Orlistat 120mg capsules reclassified from Prescription Only Medicine (POM) to Pharmacy Only Medicine (P) status with effect from 31 January 2005 to treat people who are obese (BMI of 30 or above). |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | 2009 | Slovak Republic | OTC | Orlistat 60 mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 12 January 2009. The switch was also implemented in Croatia, Norway and Switzerland. |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | 2009 | Slovenia | OTC | Orlistat 60 mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 12 January 2009. The switch was also implemented in Croatia, Norway and Switzerland. |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | — | South Korea | Rx | — |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | 2009 | Spain | OTC | Orlistat 60 mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 12 January 2009. The switch was also implemented in Croatia, Norway and Switzerland. |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | 2009 | Sweden | OTC | Orlistat 60 mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 12 January 2009. May be supplied on general sale. |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | 2009 | Switzerland | OTC | Orlistat 60mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 12 January 2009. The switch was also implemented in Croatia, Norway and Switzerland. |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | 2009 | The Netherlands | OTC | Orlistat 60 mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 12 January 2009. The switch was also implemented in Croatia, Norway and Switzerland. No product currently marketed in The Netherlands. |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | 2009 | UK | OTC | Orlistat 60mg was switched to non-prescription status under the centralised procedure in the entire European Union through a European Commission Decision dated 12 January 2009. The switch was also implemented in Croatia, Norway and Switzerland. Available as a pharmacy only medicine for weight loss in adults who are overweight (body mass index, BMI, ≥28 kg/m2) and should be taken in conjunction with a mildly hypocaloric, lower-fat diet. |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | 2007 | USA | OTC | Orlistat 60 mg capsules up to 3 times per day as a weight loss aid for overweight adults. |
| Orlistat | A Alimentary tract and metabolism. Alimentary tract and metabolism | A08. Antiobesity preparations | — | Venezuela | Rx | — |
- 41 ingredients